BioSpace News Archive

Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver and gastrointestinal diseases, today announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track designation to MET409, the company’s lead farnesoid X receptor (FXR) agonist, for the treatment of non-alcoholic steatohepatitis (NASH). “We are very pleased that MET409 has rece

Mind Medicine Inc., the leading neuro-pharmaceutical company for psychedelic inspired medicines and the University Hospital Basel’s Liechti Lab are now combining MDMA and LSD in a groundbreaking Phase 1 clinical trial.

Not even six months after launching the antiviral treatment ViralOff®, it is getting what is best described as global coverage in media. Last week culminated in an appearance on, Good Morning America - How major fashion has joined the fight against COVID-19. That, however, is only the tip of the iceberg of attention we have receive

Knight and TherapeuticsMD Announce Health Canada Approval of IMVEXXY ®

Presentation on Tuesday, September 1 st at 10:20am ET by Nephros, Inc. , today announced that it will be presenting at the LD 500 virtual investor conference on Tuesday, September 1 st at 10:20am ET. Andy Astor, President and Chief Executive Officer of Nephros

Sonnet BioTherapeutics Holdings, Inc. announced today that, as part of the previously announced warrant exchange agreement, all 3,300,066 Series A Warrants have been exercised at a price of $3.19 per share. Gross proceeds to the Company were $10.5 Million.

Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of patients with rare neurological diseases, today announced the pricing of an underwritten offering (the “Offering”) of 6,250,000 shares of its common stock. The offering price of each share of common stock was $8.00. The Offering is expected to close on August 27, 2020, subject to customary closing conditions. Cowen and Wi

Celebrating the unstoppable entrepreneurs whose ambitions transform our world

DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgaris Soluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy and did not demonstrate off-target toxicity DesCAARTes™ Phase 1 clinical trial actively recruiting patients PHILADELPHIA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T c

Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a diversified global medical aesthetics company, announced today that it has received approval from Japan’s Pharmaceutical and Medical Device Agency (”PDMA”) to market the Company’s entire OPUS line of breast implants in Japan. Sientra will market the complete portfolio of OPUS breast implants in Japan through its local partner Medical U&A, Inc. (“Medical U&A”), a leadi